Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 252 of 6351
-
Can a Triple-Drug cocktail tame resistant myeloma?
Disease control OngoingAdult patients with a confirmed diagnosis of symptomatic and relapsed and/or refractory MM, after receiving bortezomib, lenalidomide and daratumumab during first and second lines, will be eligible to be enrolled in this study. During the first three treatment cycles, patients wi…
Phase 2 • Sponsor: Tel-Aviv Sourasky Medical Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a common diabetes drug ward off Alzheimer's?
Prevention OngoingMAP will be a multi-center phase 2/3 1:1 randomized controlled trial (RCT) of long-acting metformin (reduced mass Glucophage XR) vs. matching placebo in 326 men and women with early and late aMCI, without diabetes, not treated with metformin, overweight or obese, aged 55 years to…
Phase 2/3 • Sponsor: Columbia University • Aim: Prevention
Last updated Aug 13, 2026 00:00 UTC
-
New combo pill aims to shrink spleens and ease symptoms in bone marrow cancer
Disease control OngoingThis is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase…
Phase 3 • Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Should kidney cancer patients have surgery alongside immunotherapy? a major trial aims to find out
Disease control Recruiting nowThis phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spread to other places in the body (metastat…
Phase 3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 26, 2026 15:09 UTC
-
Triple-drug inhaler aims to tame severe asthma in teens and adults
Disease control CompletedThis is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care.
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Can CAR-T cells free HIV patients from daily medication?
Disease control Recruiting nowThis is a limited-center, open-label dose escalating phase I/IIa study of autologous T cells expressing LVgp120duoCAR molecules in people with HIV infection. It will follow a 3+3 design. Dose escalation decisions will be made when a minimum of three participants have completed th…
Phase 1/2 • Sponsor: Steven Deeks • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Promising combo targets tough blood cancer before transplant
Disease control OngoingThis is a multicenter, open-label, non-randomized, phase II clinical trial conducted in Canada. The purpose of the study is to determine the remission rate of acalabrutinib in combination with R-CHOP in patients with previously untreated mantle cell lymphoma prior to autologous s…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Frozen ovary tissue reimplanted to reverse infertility after cancer
Disease control Recruiting nowChemotherapy and radiation for cancer and other conditions can cause infertility. Several centers around the world are cryopreserving ovarian tissue from these patients though an experimental protocol, including the Fertility Preservation Program in Pittsburgh (protocol PRO080504…
Sponsor: University of Pittsburgh • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Can less radiation be safer for throat cancer?
Disease control OngoingThis is a phase II, non-randomized, therapeutic trial with the primary objective to determine the efficacy of reduced contralateral (C/L) elective nodal treatment volumes in preventing C/L recurrences at 2 years in patients with p16 positive oropharyngeal squamous cell carcinoma …
Phase 2 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a drug free myelofibrosis patients from frequent blood transfusions?
Disease control OngoingThe purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF) and anemia on concomitant Janus kinase 2 (JAK2) inhibitor therapy and who require red bl…
Phase 3 • Sponsor: Celgene • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Immunotherapy plus chemo shows promise in tough lung cancer
Disease control CompletedPatients with pleural mesothelioma (PM) that cannot be surgically removed will receive standard chemotherapy (cisplatin or carboplatin and pemetrexed) given with durvalumab, a type of immunotherapy, or a treatment chosen by the study doctor, which is either standard chemotherapy …
Phase 3 • Sponsor: PrECOG, LLC. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Can more intensive therapy replace anxiety meds for kids?
Disease control OngoingPediatric onset anxiety disorders (generalized anxiety, social anxiety, separation anxiety) are highly prevalent, and if untreated, are impairing into adolescence and adulthood. In the largest comparative efficacy study remission occurred in about 65% of children and adolescents …
Phase 3 • Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Double immunotherapy attack shows promise for tough lung cancer
Disease control OngoingThis is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).
Phase 2 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Could cutting a wider margin around brain tumors extend survival?
Disease control CompletedG-SUMIT is a pilot, phase II,randomized controlled trial to evaluate the feasibility of performing a large-scale trial in patients undergoing surgery for first-time diagnosis of high grade glioma (HGG) in a surgically favorable anatomical location to answer the following: Does e…
Sponsor: Sunnybrook Health Sciences Centre • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can a new antibody boost lung cancer treatment?
Disease control OngoingThis is a phase 2 study to investigate NC318 alone or in combination with Pembrolizumab in patients with advanced non-small cell lung cancer.
Phase 2 • Sponsor: Yale University • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New combo therapy aims to fight returning head and neck cancer
Disease control OngoingTo Study Perioperative PD-1 Inhibitor and Cesium-131 Interstitial Brachytherapy in patients with locally recurrent HNSCC eligible for salvage surgery.
Phase 1/2 • Sponsor: University of Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Could adding chest radiation extend life in advanced lung cancer?
Disease control Recruiting nowThis is an open-label, single arm Phase II study designed to evaluate the efficacy and safety of thoracic radiotherapy for extensive-stage small-cell lung cancer treated with PD-1/PD-L1 plus etoposide platinum followed by PD-1/PD-L1 maintenance therapy
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Sound waves zapping liver tumors: no knife needed?
Disease control OngoingThis trial is a single arm, non-randomized prospective trial. The objective of this trial is to evaluate the efficacy and safety of the HistoSonics System for the treatment of primary or metastatic tumors located in the liver. The co-primary safety and efficacy endpoints must be …
Sponsor: HistoSonics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Can a three-drug cocktail outsmart resistant prostate cancer?
Disease control OngoingThis phase II trial investigates how well ZEN-3694, enzalutamide, and pembrolizumab work in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). ZEN-3694 blocks the expression of the MYC gene to prevent cellular gro…
Phase 2 • Sponsor: Rahul Aggarwal • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can MRI-Guided radiation boost the power of immunotherapy in head and neck cancer?
Disease control CompletedLocoregional failure remains the principal mode of mortality in head and neck squamous cell carcinoma (HNSCC) treated with conventional chemoradiation therapy. Magnetic resonance-guided radiation therapy (MRgRT) allows for adaptive radiation dose escalation based on tumor respons…
Phase 1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC